MIT Holding, Inc. (MITD) Partnership Commences Treatment of Patients in Phase 3 FDA Clinical Trial With SERRG

SAVANNAH, GA, Sep 30, 2014 (Marketwired via COMTEX) MIT Holding, Inc. (OTCQB: MITD) announces the intake of patients for a FDA clinical trial. MITD through its affiliates are acting as sub-investigators for Melinta Theraputics, the primary investigator in the study managed by SERR  G Savannah. MIT Holding, Inc. will generate revenues throughout this 12-month study. Walter Drakeford, President of MIT Holding stated, We are pleased to open this new revenue stream as a result of being selected by SERRG as a sub-investigator facility. This is evidence that our corporate re-organization and business model is capable of opening and generating new income streams through our partner affiliation programs. The facility and staff underwent intense scrutiny and was selected after a rigorous evaluation by SERRG and the State of GA. The Company is excited to continue pursuing other similar opportunities in this lucrative and specialized field. Patients will receive a two to four hour infusion in a
http://bit.ly/1vtynzq